Member Article

Arix Bioscience has led a $45m funding round in US gene therapy company

Publicly-listed healthcare investor Arix Bioscience has announced it has led in a Series B funding round for Cambridge,MA based LogicBio Therapeutics.

The $45m round, which also included backing from new investors OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI, along with previous investors OrbiMed Israel Partners.

The investment brings total funding in the business to $50m and will be put towards completing pre-clinical development and clinical studies of its disease-modifying gene therapies for orphan paediatric diseases.

As part of the funding round, Arix Bioscience’s Investment Manager, Daniel O’Connell, MD, PhD, will join LogicBio’s Board of Directors.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “Early intervention for rare genetic disorders in children is important and LogicBio is uniquely positioned at the forefront of this research area with its proprietary genetic therapy technology to deliver a durable cure for young patients with life-threatening genetic diseases and otherwise limited options.

“LogicBio has huge potential and, alongside its excellent team and investors, we look forward to supporting the company to achieve continued success in this area.”